CRD Pharmaceuticals is focused in advancing therapeutics and discover breakthrough medicines for patients with previously untreatable cancer. Cancer therapeutics is $91 billion global cancer-drug market, which will grow 5 percent annually, according to the IMS Institute for Healthcare Informatics.
CRD Pharma has a diverse portfolio of proprietary monoclonal antibodies under development with clinical trials planned for the near future. CRD Pharma’s cancer therapies are designed to target the genetics of specific tumors making it a key marker for biologic therapy. CRD33 antibody is designed at the molecular level of the cell to specifically attack and kill only the cancer cells of a specific type of cancer. CRD33 is tailor-made to recognize specific molecules unique to specific cancers. CRD33 is currently being studied as a potential treatment for pancreatic cancer and triple negative breast cancer.